Drug Trial Radar · NCT02588612
Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Last checked: Nov 20, 2026Latest source record: Sep 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Feb 1, 2016
Primary completion
Aug 10, 2020
Study completion Aug 10, 2020
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 28, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will evaluate safety and efficacy of letetresgene autoleucel (GSK3377794) in participants with metastatic NSCLC.
Conditions
- Neoplasms
Interventions
letetresgene autoleucel (GSK3377794)Drug
letetresgene autoleucel (GSK3377794) as an IV infusion.
CyclophosphamideDrug
Cyclophosphamide will be used as a lymphodepleting chemotherapy.
FludarabineDrug
Fludarabine will be used as a lymphodepleting chemotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 24 months
- Number of Participants With Hematology Results by Maximum Grade Increase Post-BaselineTime frame: Up to 24 months
- Number of Participants With Any Grade Increase in Clinical Chemistry ParametersTime frame: Up to 24 months
- Number of Participants With Worst Case Post-Baseline Abnormal Electrocardiogram (ECG) FindingsTime frame: Up to 24 months
- Change From Baseline in Oxygen SaturationTime frame: Baseline, Day 1 (pre-dose, 5, 15, and 30 minutes, 1, 1.5, 2, and 4 hours post dose), Days 2, 3, 4, 5, 8 and Week 2
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.